Danuglipron

Also known as: PF-06882961

Status

No approved product. Development discontinued. Pfizer halted the program in April 2025 after a case of potential drug-induced liver injury in a dose-optimization study. Included because discontinued candidates keep circulating in gray-market conversations long after their trials stop.

What it is

An oral small-molecule GLP-1 agonist — the same pill-not-injection ambition orforglipron achieved, from Pfizer, and the cautionary version of that story.

What published research measured

A phase 2 trial reported significant weight loss, but twice-daily dosing carried high rates of gastrointestinal adverse events and discontinuation. The once-daily reformulation met its pharmacokinetic goals — and the program was stopped anyway, on the liver signal, after a review of the full clinical database and consultation with regulators.

Caution

Development ended over a potential drug-induced liver injury. Nothing sold under this name is Pfizer clinical supply.

Source

Pfizer announcement, 14 April 2025; STAT and Reuters coverage

Sources

No linked primary source is on file for this entry yet.

Educational use only, never medical advice. No doses.